RT Journal Article
SR Electronic
T1 COVID-19 in Uganda: Predicting the impact of the disease and public health response on disease burden
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.14.20102202
DO 10.1101/2020.05.14.20102202
A1 David Bell
A1 Kristian Schultz Hansen
A1 Agnes N. Kiragga
A1 Andrew Kambugu
A1 John Kissa
A1 Anthony K. Mbonye
YR 2020
UL http://medrxiv.org/content/early/2020/06/10/2020.05.14.20102202.abstract
AB Objective COVID-19 transmission and the public health ‘lock-down’ response are now established in sub-Saharan Africa, including Uganda. Population structure and prior morbidities differ markedly between these countries from those where outbreaks were previously established. We predicted the relative impact of COVID-19 and the response in Uganda to understand whether the benefits could be outweighed by the costs.Design and setting Age-based COVID-19 mortality data from China were applied to the population structures of Uganda and countries with previously established outbreaks, comparing theoretical mortality and disability-adjusted life years (DALYs) lost. Based on recent Ugandan data and theoretical scenarios of programme deterioration, we predicted potential additional disease burden for HIV/AIDS, malaria and maternal mortality.Main outcome measures DALYs lost and mortality.Results Based on population age structure alone Uganda is predicted to have a relatively low COVID-19 burden compared to equivalent transmission in China and Western countries, with mortality and DALYs lost predicted to be 12% and 19% that of Italy. Scenarios of ‘lockdown’ impact predict HIV/AIDS and malaria equivalent to or higher than that of an extensive COVID-19 outbreak. Emerging HIV/AIDS and maternal mortality data indicate that such deterioration could be occurring.Conclusions The results predict a relatively low COVID-19 impact on Uganda associated with its young population, with a high risk of negative impact on non-COVID-19 disease burden from a prolonged lockdown response. The results are likely to reflect the situation in other sub-Saharan populations, underlining the importance of tailoring COVID-19 responses to population structure and potential disease vulnerabilities.Transparency statement The lead author affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that there are no discrepancies from the study as originally planned.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Publicly-available data only were used in the study. No IRB approval sought.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data on which the work is based are publicly available (referenced) while calculations are available from the authorsAbbreviations:List of abbreviationsAIDSAccquired Immune Defiiency SyndromeARTAntiretroviral TherapyDALYSDisability-adjusted life yearsGDPGross Domestic ProductHIVHuman Immunodeficiency VirusHMISHealth Management Information SystemIPTIzoniazid Preventive TherapyITNInsecticide-Treated NetPEPFARPresident’s Emergency Plan for AIDS ReliefSARS-CoV-2Severe Acute Respiratory SyndromeUPHIAUganda Population HIV Impact AssessmentUSAUnited States of AmericaWHOWorld Health OrganizationWS1WHO Scenario 1WS4WHO Scenario 4WS9WHO Scenario 9